Gregory Frost, Ph.D. has served as Chairman and CEO of EXUMA Biotech since 2015. Dr. Frost has over 25 years of experience in the biotechnology industry, over a decade of which leading public biotechnology companies, where he helped create over $6B worth of shareholder value during his tenure.  Dr. Frost was CEO at Halozyme Therapeutics (NASDAQ:HALO), an S&P 400 San Diego public biotechnology company he co-founded in 1999 to enable subcutaneous biologics delivery. He served in various operational roles over 15 years through multiple internal and partnered product approvals that are marketed in over 100 countries today.

Dr. Frost earned his B.A. in biochemistry and molecular biology from UCSC, his Ph.D. in the Department of Pathology at UCSF and performed postdoctoral research at the Sidney Kimmel Cancer Center. He sits on the Board of Governors at BioCom and is managing director of F1BioVentures, LLC.